Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus

Journal of Pediatrics

Volumn 148, Issue 5, 2006, Pages 571-573

  Huggins, Jennifer L ^a   Brunner, Hermine I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; RITUXIMAB;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL TRIAL; CYTOTOXICITY; DISEASE ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HUMAN; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHILD; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 33646828761     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.03.011     Document Type: Editorial

References (20)

1. Lipsky P.E. Systemic lupus erythematosus. an autoimmune disease of B cell hyperactivity. Nat Immunol 2 (2001) 764-766
2. Chan O.T., Madaio M.P., and Shlomchik M.J. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 169 (1999) 107-121
3. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
4. Stashenko P., Nadler L.M., Hardy R., et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 125 (1980) 1678-1685
5. Shan D., Ledbetter J.A., and Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48 (2000) 673-683
6. Anolik J.H., Campbell D., Felgar R.E., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
7. Sfikakis P.P., Boletis J.N., and Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus. pointing to the future. Curr Opin Rheumatol 17 (2005) 550-557
8. Leandro M.J., Edwards J.C., Cambridge G., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
9. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus. a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
10. Sfikakis P.P., Boletis J.N., Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. an open-label trial. Arthritis Rheum 52 (2005) 501-513
11. Marks S.D., Patey S., Brogan P.A., et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52 (2005) 3168-3174
12. Willems M., Haddad E., Niaudet P., et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr (2006) xxxx
13. Janwityanujit S., Totemchokchyakarn K., Verasertniyom O., et al. Age-related differences on clinical and immunological manifestations of SLE. Asian Pac J Allergy Immunol 13 (1995) 145-149
14. Arce E., Jackson D.G., Gill M.A., et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 167 (2001) 2361-2369
15. Odendahl M., Keitzer R., Wahn U., et al. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 62 (2003) 851-858
16. Odendahl M., Jacobi A., Hansen A., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165 (2000) 5970-5979
17. Jacobi A.M., Odendahl M., Reiter K., et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 1332-1342
18. Dorner T., and Lipsky P.E. Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus 13 (2004) 283-289
19. Klein U., Rajewsky K., and Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes. CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 188 (1998) 1679-1689
20. Anolik J.H., Barnard J., Cappione A., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590